Skip to main content
Premium Trial:

Request an Annual Quote

Nference Named First Partner for New Mayo Clinical Analytics Platform

NEW YORK – Mayo Clinic has unveiled its Clinical Data Analytics Platform, the first product of its recently launched Mayo Clinic Platform. Its first partner for the platform is Cambridge, Massachusetts-based Nference, a multi-omics analytics company that makes augmented intelligence and deep-learning software.

Mayo and Nference announced the news early Tuesday at the annual JP Morgan Healthcare Conference in San Francisco.

Mayo Clinic Platform is the venerable institution's new artificial intelligence-centric partnership with Google to improve healthcare delivery through digital health technologies. It is headed by John Halamka, longtime CIO of Beth Israel Deaconess Medical Center in Boston, who joined Mayo this month after serving as executive director of the Health Technology Exploration Center at Beth Israel Lahey Health.

Nference, which is developing a platform for synthesizing biomedical knowledge from scientific, regulatory, and commercial literature to support drug discovery and development, drug life cycle management, and precision medicine, will be the platform's exclusive analytics partner for the biopharmaceutical industry. Last week, Nference announced that it had closed on a $60 million Series B financing round led by Mayo Clinic Ventures.

According to Mayo, the Clinical Data Analytics Platform will focus on identifying novel drug targets and biomarkers, matching patients to proper therapies, and the analysis of "real-world evidence" for label expansion, postmarketing surveillance, and drug purposing.

"The creation of an expansive platform of deidentified clinical and molecular data that places patient privacy first is imperative for leveraging institutional knowledge," Nference Cofounder and CEO Murali Aravamudan said in a statement. "Our technology makes the predominantly unstructured biomedical knowledge computable, facilitating the discovery and development of new therapeutics."

Halamka, the new president of Mayo Clinic Platform, said that the platform model has shown to be "a force of disruption" in many business sectors. "The rapid digitalization of healthcare is affording us an unprecedented opportunity to solve complex medical problems and improve lives of people on a global scale," he added. 


The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.